Gene therapy trial aims to tame severe seizures in kids
NCT ID NCT06112275
First seen Nov 16, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a gene therapy called ETX101 in children aged 6 months to under 7 years with Dravet syndrome, a severe epilepsy. The treatment uses a harmless virus to deliver a working gene to brain cells. The main goals are to check safety and see if it reduces seizures. Only 4 children are enrolled in this early-stage trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Royal Children's Hospital
Melbourne, Australia
Conditions
Explore the condition pages connected to this study.